Coya Therapeutics, Inc. (COYA)
NASDAQ: COYA · Real-Time Price · USD
6.03
-0.04 (-0.66%)
Nov 20, 2024, 4:00 PM EST - Market closed
Coya Therapeutics Revenue
Coya Therapeutics had revenue of $9.55M in the twelve months ending September 30, 2024. In the year 2023, Coya Therapeutics had annual revenue of $6.00M.
Revenue (ttm)
$9.55M
Revenue Growth
n/a
P/S Ratio
8.78
Revenue / Employee
$1,194,289
Employees
8
Market Cap
91.78M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 6.00M | - | - |
Dec 31, 2022 | - | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionCOYA News
- 1 day ago - Coya Therapeutics CEO Dr. Arun Swaminathan Issues Letter to Stockholders - Business Wire
- 14 days ago - Coya Therapeutics Provides a Corporate Update and Reports Unaudited Third Quarter 2024 Financial Results - Business Wire
- 19 days ago - Coya Therapeutics Announces Arun Swaminathan, Ph.D. Assumes New Role as Chief Executive Officer - Business Wire
- 20 days ago - Coya Therapeutics: Buying The Dip After Unwarranted Sell-Off - Seeking Alpha
- 22 days ago - Coya Therapeutics' High-Dose Interleukin-2 Misses The Mark In Mid-Stage Alzheimer's Study - Benzinga
- 23 days ago - Coya Therapeutics reports positive immune response, safety in mid-stage Alzheimer's drug trial - Reuters
- 23 days ago - Coya Therapeutics Announces Positive Results of a Double-Blind Study of Subcutaneous Low-Dose Interleukin-2 (LD IL-2) in Alzheimer's Disease (AD) Presented at the Clinical Trials on Alzheimer's Disease Conference (CTAD24) in Madrid (Spain) - Business Wire
- 23 days ago - Coya Therapeutics Announces Conference Call to Report Results from an Investigator-Initiated Phase 2 Trial of Low-Dose Interleukin-2 in Patients with Mild to Moderate Alzheimer's Disease - Business Wire